232 related articles for article (PubMed ID: 19354342)
1. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
[TBL] [Abstract][Full Text] [Related]
2. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
4. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Devabhaktuni M; Bangalore S
Vasc Health Risk Manag; 2009; 5(1):377-87. PubMed ID: 19475775
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
8. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
[TBL] [Abstract][Full Text] [Related]
9. [Hypertension--does it matter how blood pressure is lowered?].
Mehlsen J
Ugeskr Laeger; 2008 Sep; 170(36):2782-4. PubMed ID: 18761872
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD;
Hypertension; 2009 Nov; 54(5):1009-13. PubMed ID: 19720956
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
15. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
16. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS;
Lancet Neurol; 2010 May; 9(5):469-80. PubMed ID: 20227347
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg].
De Salas M; Fernández De Bobadilla J; Ferro B; Rejas J
Farm Hosp; 2010; 34(4):170-80. PubMed ID: 20382552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
